| Table 9: | ||
|
Augmentin
Produt-Specific Considerations
|
||
|
Strength
|
Form
|
Consideration
|
| 125 mg |
CT,S
|
q8h dosing |
|
S
|
For adults having difficulty swallowing tablets, 125 mg/5 mL suspension may be substituted for 500 mg tablet | |
| 200 mg |
CT,
S
|
q12h dosing |
|
CT
|
Contains phenylalanine | |
|
S
|
For adults having difficulty swallowing tablets, 200 mg/5 mL suspension may be substituted for 875 mg tablet | |
| 250 mg |
CT,
S, T
|
q8h dosing |
|
CT
|
Contains phenylalanine | |
|
T
|
Not for use in patients weighing < 40 kg | |
|
CT,
T
|
Tablet and chewable tablet are not interchangable due to differences in clavulanic acid. | |
|
S
|
For adults having difficulty swallowing tablets, 400 mg/5 mL suspension or may be substituted for 500 mg tablet. | |
| 400 mg |
CT,
S
|
q12h dosing |
|
CT
|
Contains phenylalanine | |
|
S
|
For adults having difficulty swallowing tablets, 400 mg/ 5 mL suspension may be substituted for 875 mg tablet | |
| 500 mg |
T
|
q8h or 12h dosing |
| 600 mg |
S
|
q12h dosing |
| Contains phenylalanine | ||
| Not for use in adults or children weighing < 40 kg | ||
| 600 mg/ 5 mL suspension is not equivalent to or interchangable with 200 mg/ 5 mL due to differences in clavulanic acid. | ||
| 875 mg |
T
|
Not for use in CrCl < 30 mL/minute |
| CT=chewable tablet, S=suspension, T=tablet, ClCr=creatinine clearance | ||
|
Copyright
2002 The Cleveland Clinic Foundation
|
Return to New Antimicrobial Agents Chapter